期刊文献+

甲磺酸伊马替尼治疗慢性粒细胞白血病发生严重剥脱性皮炎一例

原文传递
导出
摘要 患者 男性,52岁,于2010年11月确诊为慢性粒细胞白血病(CML).患者以间断骨痛、腹胀、低热(最高体温38.5℃)1个月余,加重3d入院,查血常规示:白细胞计数169×10^9/L,红细胞计数3.8×1012/L,血红蛋白145g/L,血小板计数361×10^9/L,脾脏甲乙线16.9 cm,可入盆;骨髓检查:骨髓中原始细胞占骨髓有核细胞的0.012,早幼粒细胞占骨髓有核细胞的0.002,中幼粒细胞占骨髓有核细胞的0.023,晚幼粒细胞占骨髓有核细胞的0.060,嗜碱性粒细胞占骨髓有核细胞的0.032;基因检查bcr-abl基因阳性,无激酶区突变;费城染色体阳性.口服羟基脲1.0 g/次,3次/d,化疗20 d后脾脏恢复到正常大小.查血常规示:白细胞计数5.3×10^9/L,红细胞计数4.0×1012/L,血小板计数298×10^9/L,血红蛋白145 g/L,嗜碱性粒细胞0.020,复查骨髓达到完全缓解.
出处 《白血病.淋巴瘤》 CAS 2015年第8期504-504,506,共2页 Journal of Leukemia & Lymphoma
  • 相关文献

参考文献4

二级参考文献50

  • 1KantarjianHM,CortesJE,O'BrienS,et al. Imatinibmesylatetherapy in newly diagnosed patients with Philadelphia chromosome - positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses[J]. Blood,2003,101 (1):97-100. 被引量:1
  • 2Talpas M,Silver R T, Druker B J,et al. Imatinib induces durable hematologies and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study[J]. B1ood,2002,99(6):1928-1937. 被引量:1
  • 3GoldmanJM. Therapeuticstrategiesforchroniemyeloidleukemiain the chronic (stable)phase [J]. Siminars in Hematol,2003,40 (suppl 1 ):10-17. 被引量:1
  • 4Kantarjian H M,Cortes J E, O'Brien S,et al. Imatinib mesylate(STI571 )therapy for Philadelphia chromosome - positive chronic myelogenous leukemia in blast phase[J]. Blood,2002,99( 10):3547- 3553. 被引量:1
  • 5O'brienSG, DeiningerMWN. Imatinib in patients with newly diagnosed chronic phase chronic myeloid leukmia[J]. Seminars in Hematol,2003,40(suppl 2):26 -30. 被引量:1
  • 6Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med, 2002,346:645-652. 被引量:1
  • 7Cortes J, O'Brien SM, Giles F, et al. Investigational strategies in chronic myelogenous leukemia. Hematol Oncel Clin North Am,2004,18:619-639. 被引量:1
  • 8Crossman LC, O'Brien SG. Imatinib therapy in chronic myeloid leukemia. Hematol Oncol Clin North Am, 2004,18:605-617. 被引量:1
  • 9Cortes J, Giles F, O'Brien S, et al. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. Blood, 2003,102 :83-86. 被引量:1
  • 10Wolff NC, Veach DR, Tong WP, et al. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than. imatinib mesylate in a mufine model of chronic myeloid leukemia. Blood,2005,105:3995-4003. 被引量:1

共引文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部